Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Kim RB, Fromm MF, Wandel Cet al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest.101,289–294 (1998).
  Medline CASGoogle Scholar
• 2  Uhr M, Grauer MT: abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr Res.37,179–185 (2003).
  MedlineGoogle Scholar
• 3  Wang JS, Taylor R, Run Y, Donovan LJ, Markowitz SJ, DeVane CL: Olanzapine penetration into brain is greater in transgenic mdr1a P-glycoprotein deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology29,551–557 (2004).• This study demonstrated that olanzapine penetration into the brain is greater in transgenic abcb1a P-glycoprotein-deficient mice than in FVB1 (wild-type) animals.
  Medline CASGoogle Scholar
• 4  Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ: Population pharmacokinetic analysis of drug–drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl)183(4),490–499 (2006).
  Medline CASGoogle Scholar
• 5  Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S: Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog. Neuropsychopharmacol Biol. Psychiatry30(2),286–291 (2006).• This study suggested that the C3435T polymorphism of ABCB1 is associated with some therapeutic response to bromperidol in schizophrenic patients, possibly by a different drug concentration in the brain.
  Medline CASGoogle Scholar
• 6  Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry166(6),712–726 (1995).
  Medline CASGoogle Scholar
• 7  Heck AH, Haffmans PM, de Groot IW, Hoencamp E: Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr. Res.46(2–3),97–105 (2000).
  Medline CASGoogle Scholar
• 8  Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med346(1),16–22 (2002).
  Medline CASGoogle Scholar
• 9  Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr. Scand.106(5),323–330 (2002).
  Medline CASGoogle Scholar
• 10  Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci.71(2),163–169 (2002).
  Medline CASGoogle Scholar
• 11  Ejsing TB, Pedersen AD, Linnet K: P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug–drug interaction experiments. Hum. Psychopharmacol.20(7),493–500 (2005).•• The knockout mice experiments showed that both risperidone and 9-OH-risperidone interact with P-glycoprotein in vitro, and P-glycoprotein has a profound effect on risperidone and 9-OH-risperidone distribution over the blood–brain barrier.
  Medline CASGoogle Scholar
• 12  Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL: The brain entry of risperidone and 9-OH-risperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol7(4),415–419 (2004).•• These results showed that the brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.
  Medline CASGoogle Scholar
• 13  Fojo A, Lebo R, Shimizu N et al.: Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat. Cell Mol. Genet.12(4),415–420 (1986).
  Medline CASGoogle Scholar
• 14  Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7),3473–3478 (2000).•• This study observed a significant correlation of a polymorphism in exon 26 (C3435T) of MDR-1 (ABCB1) with expression levels and function of MDR-1.
  Medline CASGoogle Scholar
• 15  Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics2(1),51–64 (2001).
  CASGoogle Scholar
• 16  Furuno T, Landi MT, Ceroni M et al.: Expression polymorphism of the blood–brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics12(7),529–534 (2002).
  Medline CASGoogle Scholar
• 17  Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics.15(10),693–704 (2005).
  Medline CASGoogle Scholar
• 18  Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics13(5),259–263 (2003).
  Medline CASGoogle Scholar
• 19  Jones PM, George AM: A new structural model for P-glycoprotein. J. Membr. Biol.166(2),133–147 (1998).
  Medline CASGoogle Scholar
• 20  Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European–Americans and African–Americans. Clin. Pharmacol. Ther.70(2),189–199 (2001).
  Medline CASGoogle Scholar
• 21  Tanabe M, Ieiri I, Nagata N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther297(3),1137–1143 (2001).
  Medline CASGoogle Scholar
• 22  Morita Y, Sakaeda T, Horinouchi M et al.: MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm. Res.20(4),552–556 (2003).
  Medline CASGoogle Scholar
• 23  Verstuyft C, Schwab M, Schaeffeler E et al.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol.58(12),809–12 (2003).
  Medline CASGoogle Scholar
• 24  Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther75(1),13–33 (2004).
  Medline CASGoogle Scholar
• 25  Llerena A, Berecz R, Dorado P et al.: Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J. Chromatogr.B783,213–219 (2003).
  Google Scholar
• 26  Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res.15(2),97–98 (2005).
  Medline CASGoogle Scholar
• 27  Fanous AH, van den Oord EJ, Riley BP et al.: Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am. J. Psychiatry162(10),1824–1832 (2005).
  MedlineGoogle Scholar
• 28  Hitzl M, Drescher S, van der Kuip H et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics11(4),293–298 (2001).
  Medline CASGoogle Scholar
• 29  Siegmund W, Ludwig K, Giessmann T et al.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther.72(5),572–583 (2002).
  Medline CASGoogle Scholar
• 30  Kimchi-Sarfaty C, Gribar JJ, Gottesman MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol.62(1),1–6 (2002).
  Medline CASGoogle Scholar
• 31  Morita N, Yasumori T, Nakayama K: Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol.65(11),1843–1152 (2003).
  Medline CASGoogle Scholar
• 32  Sakaeda T, Nakamura T, Horinouchi M et al.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res.18(10),400–404 (2001).
  Google Scholar